DDInter624 DDInter210
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Delavirdine
Delavirdine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Delavirdine
Delavirdine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Delavirdine
Delavirdine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Delavirdine
Delavirdine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Vesiculobullous rash
Vesiculobullous rash {u} (Side Effect) is caused by {v} (Compound) Thalidomide
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Thalidomide
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Efavirenz {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Delavirdine (Compound) and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Delavirdine (Compound) and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Efavirenz (Compound) is included by Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class) and Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class) includes Delavirdine (Compound) and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Efavirenz (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound) and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Efavirenz (Compound) causes Vesiculobullous rash (Side Effect) and Vesiculobullous rash (Side Effect) is caused by Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Binimetinib
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Binimetinib
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Efavirenz (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Binimetinib
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Binimetinib